Latest 10-K annual reports

Veracyte, Inc. reported a significant increase in total revenue and net income for the fiscal year ended December 31, 2025, driven by strong growth in its Decipher Prostate and Afirma tests and strategic expansion into minimal residual disease diagnostics.

Janux Therapeutics' 2025 annual report highlights significant clinical advancements for its TRACTr and ARM platforms, alongside new and ongoing strategic collaborations.

Shake Shack Inc. reported significant revenue and net income growth in fiscal 2025, driven by new Shack openings and robust digital sales, despite a slight decline in guest traffic at comparable Shacks.

Columbia Banking System, Inc. reports increased net income and assets for 2025, driven by the Pacific Premier acquisition, despite a dip in diluted EPS due to share issuance.

Rocket Lab Corporation reported significant revenue growth in 2025, driven by increased launch cadence and space systems, despite a delay in its Neutron launch vehicle development.

Aclaris Therapeutics, a clinical-stage biopharmaceutical company, reported a net loss of $64.9 million for 2025, while advancing its immuno-inflammatory disease pipeline and seeking third-party partnerships.

SITE Centers Corp. reports a significant decrease in net income and FFO for 2025 as it progresses with its strategic disposition and wind-up plan, including substantial asset sales and special dividends.

Lightbridge Corporation's 2025 annual report details significant R&D investments, strategic partnerships, and substantial capital raises, while reporting increased net losses.

Adaptive Biotechnologies reported significant revenue growth and a substantial reduction in net losses for 2025, driven by its MRD business and strategic partnerships.

Mativ Holdings, Inc. reported a net loss of $337.4 million for fiscal year 2025, primarily driven by a significant goodwill impairment charge, despite a slight increase in net sales.

TTEC Holdings, Inc. reported a 3.4% revenue decrease in 2025, driven by a significant goodwill impairment in its Digital segment and reduced demand in Engage, despite improved operating cash flow.

Arcellx announced its acquisition by Gilead Sciences for $115.00 per share plus a $5.00 CVR, following FDA acceptance of its BLA for anito-cel in relapsed or refractory multiple myeloma.

FIGS, Inc. reported a 13.6% increase in net revenues to $631.1 million for 2025, driven by customer growth and higher average order value, despite a decline in gross margin due to tariffs and inventory write-offs.

The Brinks Company's 2025 annual report highlights significant revenue and operating profit increases, driven by organic growth and strategic acquisitions, alongside a major acquisition announcement for NCR Atleos.

Xperi Inc. reported a 9% decline in revenue to $448.1 million and a net loss of $56.3 million for fiscal year 2025, alongside a strategic restructuring and significant growth in TiVo One monthly active users.

Viatris Inc. reported a significant net loss of $3.51 billion for 2025, driven by a $2.94 billion goodwill impairment and declining revenues, despite advancing its strategic portfolio and pipeline.

MBIA Inc. reported a significantly reduced net loss of $177 million in 2025, driven by favorable developments in its Puerto Rico Electric Power Authority exposure.

Bright Horizons Family Solutions Inc. reported a 9% revenue increase to $2.9 billion in 2025, driven by strong back-up care utilization and full-service child care enrollment growth, despite navigating increased operating costs and a tight labor market.

Ionis Pharmaceuticals, a leader in RNA-targeted medicines, reported significant revenue growth in 2025 driven by new product launches and a robust pipeline, despite a net loss.

Crinetics Pharmaceuticals reports FDA approval for PALSONIFY in acromegaly, marking its transition to a commercial-stage company, alongside pipeline advancements and a strong capital position.

PubMatic, an AI-powered advertising technology company, reported a net loss and revenue decline in 2025, impacted by reduced political ad spend and platform changes by major buyers, while also initiating a lawsuit against Google for alleged anticompetitive practices.

Applied Optoelectronics, Inc. reported an 82.8% revenue increase in 2025, driven by strong demand in CATV and internet data center markets, despite an accumulated net loss.

TXO Partners, L.P. reported a net loss of $21.6 million in 2025 despite significant production growth and strategic acquisitions, impacted by lower oil prices and increased operating costs.

Coupang, Inc. reported a 14% increase in total net revenues to $34.53 billion for 2025, alongside a significant rise in net income, despite facing a major data incident and related legal challenges.

LSB Industries achieved a significant financial turnaround in 2025, marked by increased sales and strategic progress in low-carbon product development and carbon capture.

Ingevity Corporation finalized its strategic portfolio review in 2025, divesting its industrial specialties and CTO refinery businesses, while reporting a net loss of $167.1 million for the year, impacted by significant impairment charges and legal expenses.

PureCycle Technologies, Inc. reported its 2025 annual results, highlighting initial revenues, significant capital raises, and progress on global expansion plans despite operational challenges at its Ironton facility and a substantial net loss.

Lindblad Expeditions Holdings, Inc. reported a significant 20% increase in tour revenues for 2025, driven by higher guest numbers and strategic acquisitions, alongside a successful debt refinancing and preferred stock conversion.

Everest Group reports mixed financial results for 2025, marked by strategic divestitures, significant executive appointments, and ongoing challenges in casualty lines.

Tectonic Therapeutic, a clinical-stage biotechnology company, reported its 2025 annual financial results and provided updates on its lead product candidates, TX45 and TX2100, including ongoing clinical trials and future milestones.